Business
Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity
Paper Published in Peer-Reviewed Journal, Genes, as Part of Special Supplement on Genetics of Prader-Willi Syndrome (PWS) DCCR is the first K-ATP Channel
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"Paper Published in Peer-Reviewed Journal, Genes, as Part of Special Supplement on Genetics of Prader-Willi Syndrome (PWS)\n DCCR is the first K-ATP Channel activator being developed for PWS Company expects to report top-line data from Phase III trial evaluating DCCR for PWS patients in Q2 2020 REDWOOD CITY, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that a paper authored by Soleno’s researchers entitled, “The Potential Role of Activating the ATP-Sensitive Potassium Channel in the Treatment of Hyperphagic Obesity,” was published in the April edition of Genes, an open-access journal of genetics and genomics. The article is included in the journal’s special supplement on the genetics of Prader-Willi Syndrome (PWS), and can be accessed here: https://www.mdpi.com/2073-4425/11/4/450/htm. The ATP-sensitive potassium (KATP) channel is present in tissues that are critical to appetite regulation, and agonizing the channel is one of the primary mechanisms by which the hormones that regulate appetite, leptin, insulin and α-melanocortin stimulating hormone, exert their effects. Agonizing the channel in hyperphagic obesity results in a range of therapeutically relevant responses, including reducing appetite, improving satiety, reducing fat mass, decreasing circulating and liver fat, and improving insulin sensitivity. The publication illustrates that these responses have been observed in numerous animal models of hyperphagic obesity. These responses have also been seen in diazoxide chloride-controlled release (DCCR)-treated patients with PWS, a rare genetic form of hyperphagic obesity. DCCR is the first KATP channel agonist being developed for the treatment of PWS. “Treatment with DCCR can directly open the KATP channels in the NPY/AgRP neurons, which control appetite and energy expenditure, reducing the synthesis and secretion of NPY and AgRP, and thereby, reducing hyperphagia, the hallmark symptom of PWS. In addition, reduced secretion of insulin and improved insulin sensitivity may result in a variety of metabolic effects beneficial to PWS patients,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We have completed enrollment in our ongo...